Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
Featured news and events
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
We have a new website, with updated design and content. The site works better on mobile devices and brings together our resources, member information and programmes so they are easy to find.
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.
Fiona Walsh writes about designing around the different challenges a person with dementia may experience – and how these design decisions can have a significant impact on a person’s dignity and independence
‘Dementia Innovation Readiness Index 2020: 30 Global Cities’ calls strongly for cities to fulfil their commitments under the WHO’s Global action plan on dementia to engage fully with their national dementia plans.
On World Alzheimer’s Day, Hilary Doxford, a dementia advocate and member of the 3 Nations Dementia Working Group and World Dementia Council, shares her views and experiences – as well as those of her friends and fellow advocates – of living with dementia in the UK during the Covid-19 pandemic.